Outcomes of Kennedy Pharmacy Innovation Center's Chronic Care Management Program

May 1, 2015

Bob Davis, PharmD, FAPhA, a professor of the Kennedy Pharmacy Innovation Center, talks about the center's Chronic Care Management program and its outcomes.

Bob Davis, PharmD, FAPhA, a professor of the Kennedy Pharmacy Innovation Center, talks about the center's Chronic Care Management program and its outcomes.

This video was recorded at APhA's Annual Meeting and Exposition in March 2015.

Related Videos

Credit: wladimir1804 - stock.adobe.com

Women buying contraceptive pills in the pharmacy | Image credit: Antonioguillem - stock.adobe.com

Healthcare technology | Image credit: ipopba | stock.adobe.com

Medical science laboratory | Image credit: alphaspirit - stock.adobe.com

Gastroenterologist using digital x-ray of human intestine holographic scan projection 3D rendering | Image Credit: sdecoret - stock.adobe.com

Supreme Court | Image credit: steheap - stock.adobe.com

Pharmacists talking with a nurse | Image credit: Jacob Lund - stock.adobe.com

Related Content

Counsel Patients On the Range of Treatments for Depression

BONUS: American Association of Pharmacy Technicians Convention 2023

Migraine: Much Progress Made, Significantly More Needed

Independent Rx Forum - Congressional Trends on PBM Reform

FDA Approves Pfizer’s Paxlovid for Treatment of COVID-19 in Adults

FDA Approves Celltroin’s Yuflyma as Humira Biosimilar for 8 Disease States

Counsel Patients On the Range of Treatments for Depression

BONUS: American Association of Pharmacy Technicians Convention 2023

Migraine: Much Progress Made, Significantly More Needed

Independent Rx Forum - Congressional Trends on PBM Reform

FDA Approves Pfizer’s Paxlovid for Treatment of COVID-19 in Adults

FDA Approves Celltroin’s Yuflyma as Humira Biosimilar for 8 Disease States

Counsel Patients On the Range of Treatments for Depression

BONUS: American Association of Pharmacy Technicians Convention 2023

Migraine: Much Progress Made, Significantly More Needed

Independent Rx Forum - Congressional Trends on PBM Reform

FDA Approves Pfizer’s Paxlovid for Treatment of COVID-19 in Adults

FDA Approves Celltroin’s Yuflyma as Humira Biosimilar for 8 Disease States

Related Content

Woman struggling with depression | Image credit: Kittiphan - stock.adobe.com

Counsel Patients On the Range of Treatments for Depression

BONUS: American Association of Pharmacy Technicians Convention 2023

BONUS: American Association of Pharmacy Technicians Convention 2023

Image Credit: Adobe Stock - Artem Furman

Migraine: Much Progress Made, Significantly More Needed

Independent Rx Forum - Congressional Trends on PBM Reform

Independent Rx Forum - Congressional Trends on PBM Reform

Coronavirus | Image credit: Vector - stock.adobe.com

FDA Approves Pfizer’s Paxlovid for Treatment of COVID-19 in Adults

Biosimilar spelled on blocks | Image credit: lexiconimages - stock.adobe.com

FDA Approves Celltroin’s Yuflyma as Humira Biosimilar for 8 Disease States

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.